Recurrent Stroke - Detailed Overview

Definition and Epidemiology

• A TIA increases the risk of a subsequent stroke more than five-fold
• Approximately 10% of patients after TIA will have a stroke within 90 days, with almost half occurring within 2 days
• After the acute period, about 20% of patients with a prior TIA will have a stroke during the next 10 years
• The risk of stroke recurrence is front-loaded - the majority occur in the first 3 months after the index event
• Atrial fibrillation-related stroke carries a 6-10% annual recurrence risk
• High-grade carotid stenosis (70-99%) carries up to 25% recurrence risk over 2 years, highest in the first weeks

Risk Factors for Recurrent Stroke

Nonmodifiable Risk Factors

Modifiable Risk Factors

• Arterial hypertension - the most important treatable risk factor
• Atrial fibrillation - most common cause of cardioembolic stroke; 5-7% yearly thromboembolism risk in high-risk patients
• Diabetes mellitus - increases vascular risk; microangiopathic changes contribute
• Dyslipidemia - high LDL-C drives large-vessel atherosclerosis
• Carotid artery stenosis / intracranial atherosclerosis
• Cigarette smoking
• Obesity, physical inactivity
• Obstructive sleep apnea
• Elevated homocysteine, anticardiolipin antibodies, CRP
• Oral contraceptive use in women

Mechanisms / Etiology of Recurrent Stroke

1. Large-artery atherosclerosis - extracranial carotid or intracranial artery disease
2. Cardioembolism - atrial fibrillation, left ventricular thrombus, prosthetic valves, rheumatic mitral stenosis
3. Small-vessel (lacunar) disease - cerebral small vessel disease, often hypertension-driven
4. Other determined etiology - arterial dissection, hypercoagulable states, sickle cell disease
5. Cryptogenic - no identified cause despite full workup; PFO may be implicated especially in young patients

Cardioembolic Causes - When Anticoagulation is Standard of Care

• Atrial fibrillation or flutter
• Left atrial / ventricular thrombus
• Mechanical prosthetic valves (warfarin + antiplatelet)
• Recent anterior MI with left ventricular thrombus (<4 weeks)

Risk Stratification after TIA/Minor Stroke

ABCD2 Score

• ABCD2 score ≥4: moderate to high stroke risk - justifies hospital admission
• Note: Newer guidelines have moved toward MRI-based risk stratification over ABCD2 alone, as DWI-positive TIA patients are at substantially higher early risk

Secondary Prevention Strategies

• B - Blood pressure reduction
• L - LDL cholesterol lowering
• A - Antiplatelet therapy / A1C (glycemic control)
• S - Stroke team, Smoking cessation, Sleep apnea
• T - Telemetry (cardiac rhythm monitoring)
• E - Echocardiography
• D - Doppler (carotid), Diabetes management

1. Antihypertensive Therapy

• BP reduction is recommended even in normotensive stroke patients
• An average reduction of 10/5 mmHg is associated with approximately 25% reduction in recurrent stroke risk
• For lacunar infarctions: target systolic BP <130 mmHg starting 2 weeks after stroke significantly reduces intracerebral hemorrhage and subsequent stroke
• Preferred agents: diuretics, calcium channel blockers, ACE inhibitors, angiotensin receptor blockers
• Timing: can begin once stabilized, generally after at least 24 hours

2. Antiplatelet Therapy

• Aspirin (50-325 mg/day): first-line antiplatelet; IST and CAST trials established modest reduction in mortality and stroke recurrence when given within 48 hours of stroke
• Clopidogrel (75 mg/day): equivalent or slightly superior to aspirin alone
• Aspirin + sustained-release dipyridamole (25/200 mg twice daily): an option
• Ticagrelor alone: no better than aspirin at 90 days for combined endpoint

• For high-risk TIA or minor, nondisabling ischemic stroke: 21-30 days of DAPT with aspirin + clopidogrel (clopidogrel 600 mg loading dose on day 1, then 75 mg/day) decreases recurrent stroke by ~30% vs monotherapy, but increases major bleeding by ~40%
• Alternatively, aspirin + ticagrelor (180 mg loading dose, then 90 mg twice daily) for 30 days; more bleeding risk than the clopidogrel combination
• Short-term DAPT (21-30 days, not extended to 90 days) limits hemorrhagic risk - longer duration did not provide incremental benefit and increased bleeding
• Long-term DAPT is NOT recommended - no reduction in long-term disability and increased bleeding

• CHANCE (China): clopidogrel + aspirin reduced 90-day recurrent stroke after TIA/minor stroke without increase in major hemorrhages
• POINT (international): similar benefit but more major systemic hemorrhages with 90-day regimen
• THALES: ticagrelor + aspirin for 30 days

3. Statin Therapy (Lipid Lowering)

• All patients <75 years without safety concerns: high-intensity statin (atorvastatin 40-80 mg or rosuvastatin 20-40 mg daily)
• Patients >75 years or safety concerns: moderate-intensity statin (atorvastatin 10-20 mg, rosuvastatin 5-10 mg, pravastatin 40-80 mg)
• Target LDL <70 mg/dL: reduces subsequent major cardiovascular events and all recurrent strokes by ~20% vs target of 90-110 mg/dL (though with a non-significant higher risk of hemorrhagic stroke)
• SPARCL trial: high-dose atorvastatin reduced subsequent stroke after TIA or first stroke by 2% over 5 years
• PCSK9 inhibitors (evolocumab, alirocumab): may be added when LDL target not achieved on maximally tolerated statin + ezetimibe
• Stopping a statin acutely in ischemic stroke is associated with increased morbidity and mortality - do not discontinue

4. Anticoagulation - Cardioembolic Stroke

• Direct oral anticoagulants (DOACs) - apixaban, rivaroxaban, dabigatran, edoxaban - or warfarin (target INR 2-3) are standard of care
• DOACs are preferred over warfarin: fewer drug interactions, no routine INR monitoring, similar or slightly better efficacy
• Apixaban: slightly fewer strokes and cerebral hemorrhages vs warfarin in the ARISTOTLE trial
• CHADS2 / CHA2DS2-VASc scores guide anticoagulation initiation
• Even elderly patients at risk of falling: the overall risk of recurrent stroke generally exceeds the risk of inducing hemorrhage
• Timing after stroke: early anticoagulation carries risk of hemorrhagic transformation; the decision must weigh stroke size and hypertension; generally after at least 24 hours for small non-disabling strokes, longer for large infarcts

5. Surgical and Endovascular Interventions

• Symptomatic 70-99% stenosis: carotid revascularization (endarterectomy or stenting) reduces recurrence by 50% - benefit is high, procedure risk must be <6% morbidity
• Symptomatic 50-69% stenosis: ~16% relative risk reduction with revascularization
• <50% stenosis: no benefit from revascularization
• Carotid endarterectomy vs stenting: similar combined endpoint but stenting has higher stroke risk; younger patients do better with stenting, patients >70 years do better with endarterectomy

• Angioplasty/stenting: no benefit compared to best medical therapy (prematurely terminated due to higher complication rate in stenting arm)
• Best medical therapy for intracranial atherosclerosis: 90-day aspirin + clopidogrel + high-intensity statin

• Indicated in cryptogenic stroke patients where PFO is likely causative: age <60, embolic-appearing infarct on imaging, absence of vascular risk factors + atrial septal aneurysm
• Multiple RCTs (CLOSE, REDUCE, RESPECT) showed decreased recurrent stroke rates vs medical therapy, particularly in younger patients with large shunts

6. Glycemic Control

• Diabetes control is important; avoid both hypoglycemia and hyperglycemia
• Target HbA1c <7% for microvascular benefit (macro/cerebrovascular benefit less clear)
• Pioglitazone: one RCT showed reduced stroke/MI recurrence in patients with insulin resistance post-stroke (not yet standard)

7. Lifestyle and Other Measures

• Smoking cessation - mandatory counseling
• Physical activity: ≥30 min moderate/vigorous exercise daily
• Diet low in sodium, rich in fruits and vegetables
• Treat obstructive sleep apnea
• Alcohol: no more than 1-2 drinks/day
• Oral contraceptives or hormonal therapies: may need to be discontinued in women with stroke
• Sickle cell disease: long-term blood transfusion therapy is superior to hydroxyurea for preventing recurrent stroke

Special Situations

Cryptogenic Stroke / Embolic Stroke of Undetermined Source (ESUS)

• PFO may be implicated - evaluate for closure in appropriate candidates
• Atrial cardiopathy in ESUS may warrant anticoagulation (under study)
• Extended cardiac monitoring (loop recorder) to detect paroxysmal AF

Intracerebral Hemorrhage (ICH) with Cardioembolic Risk

• Resuming anticoagulation after ICH in high-risk AF is a major clinical dilemma
• One open-label trial showed no difference in recurrent ICH with antiplatelet therapy vs withholding it
• Ongoing RCTs (ENRICH-AF, ASPIRE, A3ICH) are addressing therapeutic anticoagulation after ICH in AF patients; some have completed by 2024-2025
• Left atrial appendage closure is an emerging alternative in this population

Small Vessel / Lacunar Stroke

• European Stroke Organisation 2024 guidelines (PMID 38380638) address secondary prevention for lacunar ischemic stroke specifically
• BP control is the cornerstone; target systolic <130 mmHg
• Long-term dual antiplatelet therapy was not beneficial in the SPS3 trial (small vessel strokes)

Prognosis

• Post-TIA: ~10% stroke risk within 90 days; ~20% over 10 years
• The strokes that do recur are frequently fatal or severely disabling
• Factors predicting higher recurrence risk: age >60, diabetes, speech/motor deficits, ischemic lesion on DWI-MRI, symptoms lasting >10 min
• Post-stroke cognitive impairment itself predicts higher recurrent stroke risk and mortality - a 2024 systematic review and meta-analysis (PMID 39239841) confirmed this association
• Inflammation markers (CRP, IL-6) predict vascular recurrence in a 2024 IPD meta-analysis (PMID 38165328), with risk varying by stroke subtype

2025 Recent Evidence Update

• Residual stroke risk despite anticoagulation in AF (JAMA Neurology, Jul 2025, PMID 40394992): a systematic review and meta-analysis found that patients on anticoagulation for AF still carry meaningful residual stroke risk, reinforcing the need for multimodal risk factor management
• Breakthrough ischemic stroke on DOACs (Neurology, 2025, PMID 40758940): a meta-analysis found switching anticoagulant class or dose escalation may reduce subsequent events
• ESO 2024 Lacunar Stroke Guideline (PMID 38380638): provides updated evidence-based recommendations specific to small vessel/lacunar stroke secondary prevention